Breast Cancer

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Discusses Adjuvant Chemotherapy Patient Selection

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity

The US Supreme Court has asked an appellate court to reconsider its decision regarding patents held on two genes.

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Dr. Neil Spector, from the Duke Cancer Institute, Discusses the Complexities of Cancer

Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, Discusses Breast Cancer Chemoprevention

Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies

Dr. Patrick Borgen, from the Maimonides Breast Cancer Center, Discusses the Negative Effects of Pinkwashing

Contrary to earlier findings, surgical breast biopsies may not be as overused as previously thought, according to a recent study published in the Journal of the American College of Radiology.

Dr. Debu Tripathy, from the USC Norris Comprehensive Cancer Center, Discusses Breast Cancer Prevention

Recognition of breast cancer subtypes and research into their underlying biologies is driving the development of new therapies.

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Adjuvant Bisphosphonates for Breast Cancer

Next-generation immunotherapy in breast cancer treatment is an active field of scientific exploration with the potential to yield a vaccine.

Dr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting

Technological advances in genomics have prompted a "sea change" in breast cancer drug development and treatment.

The choice of breast-conserving surgery over mastectomy is often based on fear of recurrence and death rather than clinical evidence.

Debu Tripathy, MD, culled the highlights from abstracts presented in 2011 at the ASCO annual meeting in Chicago, Illinois, and at the CCTR-AARC SABCS in Texas.

The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

Dr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer

The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment.

Dr. Jose Baselga from Massachusetts General Hospital Discusses the BOLERO Breast Cancer Trials

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.